Liquidia (NASDAQ:LQDA) Director Arthur Kirsch Sells 5,000 Shares

Liquidia Corporation (NASDAQ:LQDA) Director Arthur Kirsch sold 5,000 shares of Liquidia stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $56.00, for a total value of $280,000.00. Following the completion of the transaction, the director owned 10,000 shares in the company, valued at $560,000. The trade was a 33.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Liquidia Price Performance

LQDA stock opened at $55.53 on Thursday. The company has a market cap of $4.94 billion, a PE ratio of 396.66 and a beta of 0.58. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. The stock has a 50-day moving average price of $45.73 and a two-hundred day moving average price of $39.16. Liquidia Corporation has a 12-month low of $11.85 and a 12-month high of $63.46.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia’s quarterly revenue was up 4187.1% compared to the same quarter last year. As a group, research analysts predict that Liquidia Corporation will post 2.97 EPS for the current year.

Institutional Trading of Liquidia

A number of hedge funds have recently made changes to their positions in the company. Covestor Ltd raised its stake in shares of Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after purchasing an additional 359 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in Liquidia by 7.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 6,304 shares of the company’s stock worth $217,000 after purchasing an additional 422 shares in the last quarter. Quantinno Capital Management LP increased its holdings in Liquidia by 3.6% in the first quarter. Quantinno Capital Management LP now owns 17,165 shares of the company’s stock valued at $648,000 after buying an additional 589 shares during the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in Liquidia in the fourth quarter valued at about $25,000. Finally, ProShare Advisors LLC raised its stake in Liquidia by 7.1% during the fourth quarter. ProShare Advisors LLC now owns 11,756 shares of the company’s stock valued at $405,000 after buying an additional 775 shares in the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Analysts Set New Price Targets

LQDA has been the subject of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research note on Tuesday, April 21st. Lifesci Capital upgraded shares of Liquidia to a “strong-buy” rating in a report on Thursday, March 5th. Wells Fargo & Company upped their price target on shares of Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Oppenheimer increased their price target on Liquidia from $16.00 to $19.00 and gave the company an “underperform” rating in a report on Thursday, March 12th. Finally, BTIG Research raised their price objective on Liquidia from $50.00 to $59.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $50.88.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).